Centaurus Financial Inc. Takes Position in Medpace Holdings, Inc. $MEDP

Centaurus Financial Inc. acquired a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 1,814 shares of the company’s stock, valued at approximately $961,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of MEDP. Johnson Financial Group Inc. purchased a new position in Medpace in the second quarter worth $27,000. Geneos Wealth Management Inc. lifted its holdings in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares during the last quarter. Elyxium Wealth LLC acquired a new stake in shares of Medpace in the 4th quarter worth $30,000. Jones Financial Companies Lllp acquired a new stake in shares of Medpace in the 2nd quarter worth $30,000. Finally, Allied Private Wealth LLC purchased a new position in Medpace during the 2nd quarter worth $31,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Down 1.8%

Shares of MEDP stock opened at $600.65 on Friday. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90. The stock has a market cap of $16.76 billion, a PE ratio of 35.21, a price-to-earnings-growth ratio of 2.73 and a beta of 1.15. The business has a 50-day simple moving average of $565.33 and a 200-day simple moving average of $494.55.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping the consensus estimate of $3.98 by $0.27. The firm had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.Medpace’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period last year, the company earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Sell-side analysts anticipate that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Insider Buying and Selling at Medpace

In other news, Director Brian T. Carley sold 5,000 shares of Medpace stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the completion of the transaction, the director directly owned 27,825 shares of the company’s stock, valued at $16,935,129.75. The trade was a 15.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO August J. Troendle sold 4,000 shares of the business’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $620.03, for a total transaction of $2,480,120.00. Following the completion of the transaction, the chief executive officer owned 540,544 shares of the company’s stock, valued at approximately $335,153,496.32. This represents a 0.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 133,821 shares of company stock worth $81,748,135. 20.50% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on MEDP shares. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $535.00 target price on shares of Medpace in a research report on Thursday, July 23rd. Leerink Partners set a $620.00 price target on Medpace in a report on Thursday, July 23rd. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and boosted their price target for the stock from $490.00 to $515.00 in a research note on Tuesday, July 7th. TD Cowen upped their price objective on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a report on Friday, July 24th. Finally, Royal Bank Of Canada increased their price objective on shares of Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $584.18.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.